Abstract
CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Current Pediatric Reviews
Title: The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Volume: 4 Issue: 1
Author(s): Randi J. Hagerman, Susan M. Rivera and Paul J. Hagerman
Affiliation:
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Abstract: CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Export Options
About this article
Cite this article as:
Hagerman J. Randi, Rivera M. Susan and Hagerman J. Paul, The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments, Current Pediatric Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339608783565770
DOI https://dx.doi.org/10.2174/157339608783565770 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Adherence to Antiretroviral Therapies: State of the Science
Current HIV Research Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment
Current Pharmaceutical Design Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Management of Stable COPD: An Update
Current Respiratory Medicine Reviews Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design The ATP-Binding Cassette Transporter-2 (ABCA2) Increases Endogenous Amyloid Precursor Protein Expression and Abeta Fragment Generation
Current Alzheimer Research Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Current Medicinal Chemistry Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design